SCHEMBL5445375

SCHEMBL5445375

O=C(NO)c1ccc(-c2ccc(CN3CCC3)cc2)o1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
USP2 O75604 1/20 0.59
TSHR P16473 1/20 0.59
MAPK1 P28482 1/20 0.59
HSD17B10 Q99714 1/20 0.59
HDAC6 Q9UBN7 6/20 0.58
HDAC1 Q13547 4/20 0.58
HDAC8 Q9BY41 1/20 0.58
PKM P14618 1/20 0.53
L3MBTL1 Q9Y468 3/20 0.51
HDAC4 P56524 1/20 0.49
KCNH2 Q12809 1/20 0.49
HDAC3 O15379 1/20 0.48
HDAC2 Q92769 1/20 0.48
ALDH1A1 P00352 2/20 0.47
MEN1 O00255 1/20 0.47
PRKD3 O94806 1/20 0.47
HPGD P15428 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5444736 0.87 MAPT (0.55) MAPTSMN1; SMN2USP2TSHRMAPK1
SCHEMBL5459011 0.86 HRH3 (0.64) MAPTSMN1; SMN2USP2TSHRMAPK1
SCHEMBL5456267 0.85 ALDH1A1 (0.52) MAPTSMN1; SMN2USP2TSHRMAPK1
SCHEMBL14448978 0.80 HDAC8 (0.48) MAPTSMN1; SMN2USP2TSHRMAPK1
SCHEMBL5453726 0.80 DPP7 (0.50) MAPTSMN1; SMN2USP2TSHRMAPK1
SCHEMBL5446779 0.79 DPP7 (0.49) MAPTSMN1; SMN2USP2TSHRMAPK1
SCHEMBL5437763 0.79 KDM4E (0.51) MAPTSMN1; SMN2USP2TSHRMAPK1
SCHEMBL5453734 0.78 ALDH1A1 (0.53) MAPTSMN1; SMN2USP2TSHRMAPK1
SCHEMBL5452549 0.76 HDAC3 (0.56) MAPTSMN1; SMN2MAPK1HSD17B10HDAC6
SCHEMBL12472215 0.74 HDAC6 (1.00) HDAC6HDAC1HDAC8HDAC4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167499-A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications A*BIO PTE LTD. (SG) 2007-07-19 US disclosed
US-20070167499-A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications A*BIO PTE LTD. (SG) 2007-07-19 US disclosed
US-20070167499-A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications A*BIO PTE LTD. (SG) 2007-07-19 US disclosed
WO-2005040161-A1 BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S*BIO PTE LTD (SG) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167499-A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications HDAC1, HDAC11, HDAC2 MAPT 3965/4885SMN1; SMN2 4348/4885USP2 2725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.